BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 2068476)

  • 21. Aztreonam. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.
    Brogden RN; Heel RC
    Drugs; 1986 Feb; 31(2):96-130. PubMed ID: 3512234
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical studies of aztreonam in Japan.
    Hara K; Kobayashi H; Nishiura T; Yura J; Saito A
    Rev Infect Dis; 1985; 7 Suppl 4():S810-24. PubMed ID: 3909341
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of aztreonam and tobramycin in the treatment of lower respiratory tract infections caused by gram-negative bacilli.
    Nolen TM; Phillips HL; Hall HJ
    Rev Infect Dis; 1985; 7 Suppl 4():S666-8. PubMed ID: 3909321
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical experience with aztreonam in Germany and Austria.
    Stille W; Gillissen J
    Rev Infect Dis; 1985; 7 Suppl 4():S825-30. PubMed ID: 3909342
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Well-controlled comparative study on aztreonam and cefoperazone in the treatment of complicated urinary tract infections].
    Ohmori H; Kumon H; Kumamoto Y; Sakai S; Niijima T; Kishi H; Ohkoshi M; Kawamura N; Naide Y; Nishiura T
    Jpn J Antibiot; 1986 Jan; 39(1):24-56. PubMed ID: 3517407
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Aztreonam in the treatment of bone and joint infections caused by gram-negative bacilli.
    Simons WJ; Lee TJ
    Rev Infect Dis; 1985; 7 Suppl 4():S783-8. PubMed ID: 2934786
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Clinical efficacy of aztreonam in patients with complicated urinary tract infections].
    Yoshida K; Uchijima Y; Kobayashi N; Suwata J; Nakame Y; Saitoh H; Negishi T; Yamada T; Kageyama Y; Kura N
    Hinyokika Kiyo; 1988 Dec; 34(12):2225-32. PubMed ID: 3071130
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Clinical evaluation of aztreonam for complicated urinary tract infection].
    Moriguchi R; Yamagoshi T; Nagakubo I; Aoki S
    Hinyokika Kiyo; 1985 Sep; 31(9):1675-80. PubMed ID: 4083224
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical experience with aztreonam.
    Stutman HR
    Pediatr Infect Dis J; 1989 Sep; 8(9 Suppl):S109-12; discussion S128-32. PubMed ID: 2682508
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of aztreonam in the treatment of severe bacterial infections.
    Romero-Vivas J; Rodríguez-Créixems M; Bouza E; Hellín T; Guerrero A; Martínez-Beltrán J; García de la Torre M
    Antimicrob Agents Chemother; 1985 Aug; 28(2):222-6. PubMed ID: 3834832
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and safety of aztreonam in the treatment of patients with renal failure.
    Sion ML; Pyrpasopoulos M; Nicolaidis P; Papagianni C; Tsurutsoglu G
    Rev Infect Dis; 1991; 13 Suppl 7():S652-4. PubMed ID: 2068477
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical evaluation of aztreonam therapy for serious infections due to gram-negative bacteria.
    McKellar PP
    Rev Infect Dis; 1985; 7 Suppl 4():S803-9. PubMed ID: 3909340
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A comparative analysis of aztreonam + clindamycin versus tobramycin + clindamycin or amikacin + mezlocillin in the treatment of gram-negative lower respiratory tract infections.
    Rivera-Vazquez CR; Ramirez-Ronda CH; Rodriguez JR; Saavedra S
    Chemotherapy; 1989; 35 Suppl 1():89-100. PubMed ID: 2659296
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The use of aztreonam in pediatric patients: a review.
    Bosso JA; Black PG
    Pharmacotherapy; 1991; 11(1):20-5. PubMed ID: 1902290
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical experience with aztreonam in Europe: a summary of studies in Belgium, England, Finland, Ireland, the Netherlands, Norway, Portugal, and Sweden.
    Norrby SR
    Rev Infect Dis; 1985; 7 Suppl 4():S836-9. PubMed ID: 2934788
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The use of aztreonam in serious gram-negative infections.
    Smith G; Bunney RG; Farrell ID; Wood MJ
    J Antimicrob Chemother; 1988 Feb; 21(2):233-41. PubMed ID: 3283094
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of aztreonam plus clindamycin with tobramycin plus clindamycin in the treatment of intra-abdominal infections.
    Birolini D; Moraes MF; de Souza OS
    Chemotherapy; 1989; 35 Suppl 1():49-57. PubMed ID: 2659290
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Clinical reevaluation of aztreonam (AZT) on urinary tract infections].
    Kohri K; Kurita T; Sakaguti H; Kadowaki T; Iguti M; Kanda H; Nagi N; Kataoka K; Kawamura M; Mitsubayashi S
    Hinyokika Kiyo; 1989 Apr; 35(4):711-6. PubMed ID: 2660527
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Clinical evaluation of aztreonam for infections accompanying febrile neutropenic children with hematologic disorders and solid tumors. A cooperative study].
    Hirotsu T; Akatsuka J; Hoshi Y; Uchiyama H; Fujisawa K; Kobayashi N; Ishidoya N; Ohira M; Takayama J; Ishida Y
    Jpn J Antibiot; 1990 Dec; 43(12):2069-77. PubMed ID: 2086821
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Aztreonam therapy for complicated urinary tract infections caused by multidrug-resistant bacteria.
    Cox CE
    Rev Infect Dis; 1985; 7 Suppl 4():S767-71. PubMed ID: 3909335
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.